You can't tell whether this might have any possibility of succeeding since no research is referred or linked to. No clue on how this might actually work other than 'magic occurs here'.
http://www.digitaljournal.com/pr/3144750
MOUNTAIN VIEW, CA, November 16, 2016 /24-7PressRelease/ -- Juno
Biomedical, Inc. announced today that it has entered into a partnership
with Promenade Software, Inc. to develop the software for Juno
Biomedical's CELLTech(TM) device.
Based on over 30 years of research in the cell electrotaxis field,
CELLTech(TM) could be the solution for those who are suffering with
motor function loss after an ischemic stroke.
"It is very important to us that our device is not only safe and
effective in returning motor function to those who are disabled after a
stroke, but that it additionally takes into account patient
functionality," says Trisha Pfluger,
CEO. "This means integrating software that can monitor and optimize the
patient's physical improvement while offering features that allow the
patient and the patient's caregivers and family to be at the center of
her therapy."
Stroke remains the #1 cause of long-term disability in the United
States, yet has no safe and effective FDA-approved regenerative
treatment, leaving millions of individuals left behind by our current
medical model.
Frances Cohen, President of Promenade Software, Inc. said: "We are
looking forward to assisting Juno Biomedical in bringing CELLTech(TM) to
fruition in a modern, interconnected software system that will help
stroke victims in ways previously unavailable."
The software component of CELLTech(TM) adds a new layer of
customizations such as real time, feedback-based remote patient
monitoring and higher granularity of dose control that is not currently
available with traditional drug therapies.
"Our exciting technology has been proven in animal models and is now
ready to be tested in humans. Working with Promenade software further
enhances the reliability of the data we plan to collect in clinical
trials and our ability to optimize patient outcomes in a short amount of
time," said Dr. Davit Mrelashvili, Chief Medical Officer, Juno Biomedical, Inc.
The field of medicine is undoubtedly moving to integrate more
exponential technologies such as digital health, regenerative therapies
and personalized medicine. While designing CELLTech(TM), the team
continues to leverage these technologies in a way that will remove
previously seen glass-ceilings in medicine.
"This technology has the potential to save a tremendous amount of money
by decreasing cost to the patient and insurance companies, while
increasing top-line revenue for major stroke hospitals," says Allan Bernstein,
MD, Medical Director of Sonoma West Research Institute and Clinical
Advisor to Juno Biomedical. "Because of this, we have a clear path to
market that not only fills an enormous need, but does so in a way that
can reduce the current economic burden that has arisen from current
limitations of stroke rehabilitation."
The Juno Biomedical team spent almost a year searching for the right
software partner before choosing Promenade. "Promenade Software has a
successful track record of developing embedded applications for both
wearable and implantable medical technologies, while maintaining the
necessary regulatory compliance for FDA submissions", said Mike Bellon,
Chief Technology Officer, Juno Biomedical, Inc. "Promenade is the right
company to help us bring our much-needed therapy to market for stroke
survivors across the globe."
The next step for Juno Biomedical is to translate its therapy to human trials in an upcoming study, projected to begin in 2017.
"We have individuals around the globe contacting us for an opportunity
to take part in our upcoming study. If proven successful in clinical
trials, patients living with severe disability will have a better
option," said CEO Trisha Pfluger. "With more sophisticated technologies
available than ever before, these are exciting times for Juno Biomedical
and for the field of medicine globally. Most importantly, these are
exciting times for those suffering the painful reality of long-term
physical disability after stroke."
About Juno Biomedical, Inc.
Juno Biomedical was launched in 2014 by scientist, author and inventor
Trisha Pfluger with an aim to transform the standard of care for persons
with neurological impairment. Founded on the idea that patient care
should heal the underlying cause of disease in a patient-centric manner,
rather than merely alleviating the symptoms, Juno Biomedical endeavors
to integrate technologies such as digital patient monitoring,
bioelectric therapy, and tissue regeneration to create an innovative
medical device that can heal brain tissue damage. The company is
pioneering advances not only in healing, but in personalized, in-home
medical care. For further information visit JunoBiomedical.com.
About Promenade Software, Inc.
Promenade Software Inc. offers a full suite of software development,
test, and regulatory services for medical and other safety critical
systems. The company's highly skilled and experienced engineers design
in test, maintainability, and quality to every project they do.
Promenade's ready-made R&D and test tools help an entire team get
their system to market quickly. For further information visit
PromenadeSoftware.com
No comments:
Post a Comment